Ploumen EH, Buiten RA, Doggen CJM, et al. - By pooling patient-level data of participants (n = 9,204) in the TWENTE, DUTCH PEERS, BIO-RESORT, and BIONYX (TWENTE I-IV) randomized trials, researchers evaluated 1-year clinical result of octogenarians managed with new-generation drug-eluting stent (DES) vs younger patients. Target vessel failure (TVF), a composite of cardiac mortality, target vessel–related myocardial infarction (MI), or clinically indicated target vessel revascularization, was the main clinical endpoint. Findings revealed the presence of more comorbidities as well as a higher incidence of the main endpoint TVF among octogenarian participants in 4 large-scale randomized DES trials. Higher cardiac mortality was reported in octogenarians, whereas no rise in MI or target vessel revascularization rates was observed. It seems new-generation DES affords a safe and effective option to treat octogenarian patients.